Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Octagam is a human normal immunoglobulin (IGIV) solution for intravenous administration.
Octagam 5% is currently registered in more than 60 countries. This study will evaluate the
efficacy, safety and the kinetics of Octagam 10% for replacement therapy in primary
immunodeficiency diseases.